Non-alcoholic Steatohepatitis (NASH) is a severe liver inflammation condition and damage caused by fat accumulation in the liver. It is an advanced form of non-alcoholic fatty liver disease (NAFLD), which is a condition that occurs when fatty acids and triglycerides build up in large amounts in the cytoplasm (within the hepatocytes) of non-alcohol users. NAFLD is caused by the build-up of fat in the liver. Even though NASH does not always progress to its more severe forms, it mostly results in cirrhosis, which is a potentially life-threatening condition leading to scarring of the liver. It can also develop into hepatocellular carcinoma (HCC) – one of the most common forms of liver cancer – at a highly advanced stage of the disease.
The condition is not
always symptomatic; however, some of the disease’s common symptoms include fatigue
and a (mild) pain in the upper right abdomen. Some of the significant symptoms,
such as quick bleeding or bruising, itchy skin, loss of appetite, jaundice,
nausea, fluid accumulation in the abdomen, swollen legs, and slurred speech,
indicate the gradual progression of the condition to liver cirrhosis. Overweight
or obese people are most susceptible to this condition. Other significant
causes and risk factors associated with NASH include diabetes, high cholesterol,
excessive accumulation of triglycerides, imbalanced diet, metabolic syndrome,
sleep apnea, hypothyroidism, and polycystic ovary syndrome. One of the most
widely used non-invasive diagnostic procedures for NASH is a liver biopsy. A
small piece of tissue is removed from the liver during the liver biopsy for
microscopic examination to determine if liver inflammation or scarring has occurred.
The
growth of the global Non-alcoholic Steatohepatitis (NASH) market is foreseen to
gain momentum in the forthcoming years. Numerous factors, such as the growing
adoption of a sedentary lifestyle and the rising prevalence of obesity and
diabetes among the populace, are expected to support the global market growth.
Several other parameters affecting the market growth include the escalating
prevalence of NASH, surging demand for NASH therapeutics, and the potential launch
of various pipeline drugs. Vitamin E, Pioglitazone,
Elafibranor, Ocaliva, Cenicriviroc, and
Selonsertib are the most common types of drugs used globally for the treatment
of NASH. Presently, there is no drug or therapeutic for NASH treatment with an
FDA clearance. The first-line approach to treating patients with NASH are
lifestyle interventions, and Vitamin E and Pioglitazone are among the most recommended
drugs.
Allergan plc (Tobira Therapeutics), Conatus Pharmaceuticals
Inc., Cadila Healthcare Limited, Gilead Sciences, Inc., Gemphire Therapeutics
Inc., Galmed Pharmaceuticals Ltd., Genfit SA, Novartis International AG, Shire
Plc, and Intercept Pharmaceuticals, Inc. are the key players operating across
the global
Non-alcoholic Steatohepatitis (NASH) market. In April 2019, Gilead had
announced positive results from its NASH clinical research program at the
International Liver Congress 2019. The data supported the company’s efforts to
develop specific combination therapies for the disease and helped evaluate the
safety and efficacy of the non-invasive tests done for its diagnosis.
Read full press release at: https://www.reportsanddata.com/press-release/global-non-alcoholic-steatohepatitis-nash-market
No comments:
Post a Comment